With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Most patients expressed an interest in understanding how environmental-climate factors affect their atopic dermatitis.

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.

JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The journal concluded that ...

To help you find the best eczema-friendly skin care products, I tapped several dermatologists for their insights and product recommendations.

Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...

The cold, dry air of winter brings challenges for those with chronic hand eczema. Chronic hand eczema (CHE), defined as hand ...

Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis.

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.